Your browser doesn't support javascript.
loading
Pathological overview of steatohepatitic hepatocellular carcinoma in a surgical series.
Trapani, Loïc; Beaufrère, Aurélie; Hobeika, Christian; Codjia, Tatiana; Albuquerque, Miguel; Bouattour, Mohamed; Lesurtel, Mickael; Cauchy, François; Paradis, Valérie.
Afiliación
  • Trapani L; Université Paris Cité, Paris, France.
  • Beaufrère A; AP-HP.Nord, Department of Pathology, FHU MOSAIC, Beaujon Hospital, Clichy, France.
  • Hobeika C; Université Paris Cité, Paris, France.
  • Codjia T; AP-HP.Nord, Department of Pathology, FHU MOSAIC, Beaujon Hospital, Clichy, France.
  • Albuquerque M; Centre de Recherche sur l'Inflammation, INSERM UMR 1149, Paris, France.
  • Bouattour M; AP-HP, Department of HPB and digestive surgery, Pitié-Salpétrière Hospital, Paris, France.
  • Lesurtel M; Centre de Recherche sur l'Inflammation, INSERM UMR 1149, Paris, France.
  • Cauchy F; AP-HP.Nord, Department of HPB surgery, Beaujon Hospital, Clichy, France.
  • Paradis V; AP-HP.Nord, Department of Pathology, FHU MOSAIC, Beaujon Hospital, Clichy, France.
Histopathology ; 83(4): 526-537, 2023 Oct.
Article en En | MEDLINE | ID: mdl-37222200
ABSTRACT

AIMS:

According to the last WHO classification, steatohepatitic hepatocellular carcinoma (SH-HCC) is recognized as a distinct HCC subtype, even though a consensual definition is still lacking. The objectives of the study were to carefully describe the morphological features of SH-HCC and evaluate its impact on prognosis. METHODS AND

RESULTS:

We conducted a single-centre retrospective study including 297 surgically resected HCC. Pathological features including SH criteria (steatosis, ballooning, Mallory-Denk bodies, fibrosis, and inflammation) were assessed. SH-HCC was defined by the presence of at least four of the five SH criteria and the SH component represented >50% of the tumour area. According to this definition, 39 (13%) HCC cases corresponded to SH-HCC and 30 cases (10%) corresponded to HCC with an SH component (<50%). SH criteria in SH-HCC and non-SH-HCC were distributed as follows ballooning (100% versus 11%), fibrosis (100% versus 81%), inflammation (100% versus 67%), steatosis (92% versus 8%), and Mallory-Denk bodies (74% versus 3%). Inflammation markers (c-reactive protein [CRP] and serum amyloid A [SAA]) were significantly more expressed in SH-HCC compared to non-SH-HCC (82% versus 14%, P = <0.001). Five-year recurrence-free survival (RFS) and 5-year overall survival (OS) were similar for SH-HCC and non-SH-HCC (P = 0.413 and P = 0.866, respectively). The percentage of SH component does not impact OS and RFS.

CONCLUSION:

We confirm in a large cohort the relatively high prevalence (13%) of SH-HCC. Ballooning is the most specific criteria for this subtype. The percentage of the SH component does not impact prognosis.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Carcinoma Hepatocelular / Hígado Graso / Neoplasias Hepáticas Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Histopathology Año: 2023 Tipo del documento: Article País de afiliación: Francia

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Carcinoma Hepatocelular / Hígado Graso / Neoplasias Hepáticas Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Histopathology Año: 2023 Tipo del documento: Article País de afiliación: Francia